Oncotelic grants 17,796 RSUs to executives tied to exchange uplisting by June 2027

Oncotelic Therapeutics, Inc.

17,796 RSUs granted to directors, officers, employees, and advisors; each RSU convertible into 1,000 common shares via Series A Preferred.
CEO Vuong Trieu receives 2,000 RSUs; CMO Anthony Maida and CBO Saran Saund each receive 1,500; CFO Amit Shah receives 1,500.
RSUs vest only if common stock uplists to a national exchange (e.g., Nasdaq, NYSE) on or before June 30, 2027, plus 6 months service.
If uplisting does not occur by June 30, 2027, all RSUs expire; change in control accelerates full vesting.
Potential dilution: up to 17.8 million common shares if all RSUs vest and Preferred converted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.